Best Stock Report – Penny Stock Newsletter Tracking

“This tiny company has developed a new way
to spot cancer cells so far in advance…

The cure rate can be 90% to 95%.

This is NOT a theory — they’ve already done it!

“Here’s why I see this $0.80 stock hitting $28 in twelve months…”

I’m not going to overwhelm you with terms you need a PhD to understand since the big idea is actually very easy to understand:

Cancer cells are like spies. They blend in so they’re hard to find and therefore difficult to stop.

MabCure (MBCI) invented a brilliant new way to spot and successfully “mark” them at their earliest stage so that they stand out and can then be eliminated. This opportunity is Immense. The market for this therapy will soon reach $22 billion a year and it’s growing 30%a year.

DO NOT Wait until this $0.80 stock hits the headlines…

Dear Investor:

To understand what I’m about to tell you, you have to almost think in military terms for a moment. Then it all becomes crystal clear.

It will take you two minutes and the payoff can be so huge, MabCure (MBCI) could easily be the greatest gainer you’ve ever bought.

Sure, Alpharma went from $3 to $61, turning $5,000 into $101,500—and Chattem soared from $2 to $79, producing a $197,500 gain on a $5,000 investment.

But even these giants have not matched the accomplishment of this tiny, unknown enterprise—revolutionizing the attack on cancer to the point where this illness could be taken off the most feared list.

MabCure (MBCI) is just $0.80 a share at the time of this writing, and I’m predicting it can reach $28 in the next twelve months. Here’s why it could actually go much, much higher.

Let’s return to my military example so you can quickly understand the enormity of their accomplishment.

You’re fighting an enemy that you can defeat. You have vastly superior firepower. And when you catch them, you always win. It’s like guerrilla warfare.

The problem is catching them. They’re evasive, shrewd and very difficult to detect before they strike with devastating effectiveness. Now imagine this.

You developed a way that lets you locate every single one of them well before they can harm you. I’d say that you’ve won the war. That’s precisely what MabCure (MBCI) has done for melanoma, prostate and ovarian cancer.

The Rules Have Changed: You’ve Stripped Away their Hiding Places, Turned the Light On, They’re Cornered. You’re Finally Winning the War

MabCure (MBCI) has developed a series of antibodies that can mark cancer cells at their earliest stages. I’m going to assume that your knowledge of medical terms equals mine—you need things explained so you can understand them. An antibody is simply a protein molecule that attaches itself to a cancer cell so the cancer cell can then be found.

Think of the antibody as a friend planting a bright orange “flag” in the target so it can be destroyed using existing treatments. This extremely specific, safe, no-side-effects targeting of cancer cells has HUGE benefits.

What options do we have today for killing these cells? Chemotherapy is a non-specific method of attack. This simply means that it destroys all the cells it touches, including healthy ones, weakening the immune system. This is one reason why patients get so sick.

When You Find Out What Chemotherapy Really
Does and How Ineffecive It Is, You Wonder,
“Why Aren’t They Telling Us This?”
It’s THAT Bad!

I asked a doctor friend of mine why So many people are on chemotherapy. His answer greatly surprised me. He said, “When a family member gets sick, the family expects us to do something. This is the best we have at the moment.”

Chemotherapy is the country’s most popular way of “fighting back.” However, when you learn the facts by looking at the statistics, it’s truly appalling. Its side effects are awful and its success rate is so low, it’s eye-opening.

This is very important because it gives you a sense just how valuable MabCure’s discovery is. We now have a new and better option that locates only cancer cells.

Chemotherapy works by targeting ALL cells, including the healthy ones. That’s like getting rid of the criminals on a city block by leveling the entire block with endless carpet bombing. It makes no sense. Here’s what experienced doctors and institutions report…

• Dr. John Diamond says it might work 7%of the time: “Chemotherapy’s success record is poor. It can achieve remissions in about 7% of all human cancers. This type of survival is not the same as a cure or even restored quality of life.”

• Chemotherapists admit that they wouldn’t take Chemotherapy: Dr. Mercola reports, “It’s especially telling that in a number of surveys, most chemotherapists have said that they would not take chemotherapy themselves or recommend it for their families.”

• John Hopkins University calls it a real failure: “Destroying cells with whole body chemotherapy has a dismal record…”

• Dr. Ulrich Abel reports on the “appalling” results: “Success of most chemotherapy is appalling. There is no scientific evidence for its ability to extend in any appreciable way the lives of patients…”

• Dr. Ralph Moss says there’s no proof it works: “There is no proof that chemotherapy in the vast majority of cases actually extends life…”

• The non-profit medical organization, Alternative Medicine says it will kill you first: “Chemotherapy strong enough to kill the cancer would have to be strong enough to kill us first.”

Compare this approach to the one MabCure (MBCI) invented. The MabCure breakthrough can target only cancer cells for elimination and there are NO terrible side effects like chemotherapy which poisons every cell, including healthy ones.

When I say that MabCure is going to revolutionize this field, this is exactly what I mean. It’s not a slogan or a far-off hope. It’s not a grand dream of mankind. It’s already been invented, it’s here and the results are beyond impressive.

This is why I’m so convinced that shares in MBCI could rocket as high as $28 a share.

I urge you to read more about MabCure by following the link below and to consider adding MabCure shares to your portfolio.

Best of Luck,

Eric Dickson, Editor
Breakaway Stocks

Read More About MabCure

IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Breakaway Stocks does not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Breakaway Stocks or an offer or solicitation to buy or sell any security. MabCure, (MBCI), the company featured in this issue, appears as paid advertising, paid by Wexford Ventures, Ltd. to provide public awareness for MBCI. Wexford Ventures, Ltd. has approved and signed off as “approved for public dissemination” all statements made herein regarding MBCI’s history, assets, technologies, current as well as prospective business operations and industry information. Breakaway Stocks and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Breakaway Stocks about MBCI. Although the information contained in this advertisement is believed to be reliable, Breakaway Stocks and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. Breakaway Stocks is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state security administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $100,000 for this and other online advertising efforts and will retain any amounts over and above the cost of production, copywriting services ,mailing and other distribution expenses, as a fee for its services. Breakaway Stocks is paid $500 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from MabCure’s investor relations firm, or at MabCure’s website www.mabcure.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like MabCure, advice to investors and other investor resources are available at the Securities and Exchange Commissionwebsitewww.sec.gov andwww.nasd.com. Any investment should be made only after consulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, MabCure notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the Company’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc. .

============================================================
============================================================

This is an advertisement from SmallCapInvestor.com (http://www.smallcapinvestor.com)

This is a paid advertisement provided to our customers. Although we have sent you this email, SmallCapInvestor.com does not endorse this product or company nor is it responsible for the content of this ad. Furthermore, we make no guarantee or warranty about what is advertised above, and have not independently reviewed the information provided within this advertisement.

Business Financial Publishing, publisher of Smallcapinvestor.com has been paid a total of twenty thousand dollars by Capital Financial Media, LLC on behalf of Macbcure (OTCBB:MBCI.OB) for the distribution of this and other email advertisements. The opinions represented in this email advertisement are not those of Business Financial Publishing.

We respect your privacy and therefore this email has been sent directly from SmallCapInvestor.com. SmallCapInvestor.com does not provide our email lists and other data to third parties. This is consistent with our Privacy Policy as outlined on our web site. You may review our Privacy Policy at: http://www.smallcapinvestor.com/content/privacy/privacy